Posted inBiotechnology
Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a…
Posted inBiotechnology
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
Servier has struck a deal to buy Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, gaining control of a…
Posted inBiotechnology
Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide (GLP) portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from…
Posted inGenetics
StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results
An Agilent Technologies researcher using the company's Agilent 1290 Infinity II Bio LC System, an ultrahigh-performance liquid chromatography (UHPLC) platform…